First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter?

Michels, Jorg; Montemurro, Trina; Kollmannsberger, Christian; Murray, Nevin; Chi, K. N.

doi:10.1200/jco.2005.23.16_suppl.4611

Cited by 28 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sample size was based on a Simon twostage minimax design [17] to evaluate the null hypothesis that the true PSA response rate was less than 10% and the alternative hypothesis that the true PSA response was more than 30%, with both a type I and II errors equal to 10%. The PSA response rate of the null hypothesis was based on the PSA response rate of 12% reported with second-line mitoxantrone after first line docetaxel, considering that mitoxantrone was the standard second-line treatment at the time this study was designed [18]. Sixteen patients had to be recruited for the first stage.…”

Section: Statistical Analysesmentioning

confidence: 99%

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

Buonerba

Federico

D’Aniello

et al. 2011

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Statistical Analysesmentioning

confidence: 99%

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

Buonerba

Federico

D’Aniello

et al. 2011

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…[11][12][13][14][15] For now, mitoxantrone is considered the de facto second-line chemotherapy, but has limited activity and increased toxicity in this setting.…”

Section: Second-line Systemic Chemotherapymentioning

confidence: 99%

Guidelines for the management of castrate-resistant prostate cancer

Saad¹,

Hotte²

2010

CUAJ

118

View full text Add to dashboard Cite

DefinitionCastrate-resistant prostate cancer (CRPC) is defined by disease progression despite androgen depletion therapy (ADT) and may present as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of preexisting disease, and/or the appearance of new metastases.Advanced prostate cancer has been known under a number of names over the years, including hormone-resistant prostate cancer (HRPC) and androgen-insensitive prostate cancer (AIPC). Most recently, the terms CRPC or castration recurrent prostate cancer were introduced with the realization that intracrine/paracrine androgen production plays is significant in the resistant of prostate cancer cells to testosterone suppression therapy. 1 In their second publication, the Prostate Cancer Working Group (PCWG2) defined CRPC as a continuum on the basis of whether metastases are detectable (clinically or by imaging) and whether the serum testosterone is in the castrate range by a surgical orchidectomy or medical therapy. 2 This continuum creates a clinical-states model where patients can be classified. The rising PSA states (castrate and noncastrate) signify that no detectable (measurable or non-measurable) disease has ever been found. The clinical metastases states (castrate and noncastrate) signify that disease was detectable at some point in the past, regardless of whether it is detectable now.Prognosis is associated with several factors, including performance status, presence of bone pain, extent of disease on bone scan and serum alkaline phosphatase levels. Bone metastases will occur in 90% of men with CRPC and can produce significant morbidity, including pain, pathologic fractures, spinal cord compression and bone marrow failure. Paraneoplastic effects are also common, including anemia, weight loss, fatigue, hypercoagulability and increased susceptibility to infection.CRPC presents a spectrum of disease ranging from patients without metastases or symptoms with rising PSA levels despite ADT, to patients with metastases and significant debilitation due to cancer symptoms.

show abstract

“…Until 2010, mitoxantrone was considered the de facto second-line chemotherapy, but published series suggest that it has limited activity and increased toxicity in that setting, with response rates from retrospective series in the range 9%-20% 18,19 .…”

Section: Second-line Systemic Chemotherapymentioning

confidence: 99%

Management of Castration-Resistant Prostate Cancer: A Global Approach

Saad

2012

Current Oncology

View full text Add to dashboard Cite

Treatment options for castration-resistant prostate cancer (CRPC) have evolved since the start of the 2000s, with most of the new effective therapies appearing since 2010. In 2004, docetaxel was the first chemotherapeutic agent to improve survival in CRPC, but little else was available once patients recurred. Since 2010, four new options have been shown to improve survival in patients with refractory or recurring disease after docetaxel. In the management of bone metastases, two bone-targeted therapies have been shown to reduce the risk of bone complications, and they are part of the overall management strategy in CRPC patients. Therapeutic options before chemotherapy have shown promising results and may soon become available in Canada. The present article reviews the treatment options that have shown to be effective in CRPC and also some of the ongoing work in the field.

show abstract

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter?

Cited by 28 publications

References 0 publications

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

Guidelines for the management of castrate-resistant prostate cancer

Management of Castration-Resistant Prostate Cancer: A Global Approach

Contact Info

Product

Resources

About